Literature DB >> 26767053

Infrequent chemoradiation-induced acute esophagitis in the Asian population: A meta-analysis of published clinical trials for unresectable stage III non-small cell lung cancer.

Takefumi Komiya1, Shana L Palla2, Feng Wang3, Raymond P Perez1, Chao H Huang4.   

Abstract

Severe (grade 3 or higher) esophagitis is one of the major toxicities for chemoradiation in the treatment of stage III non-small cell lung cancer (NSCLC). The difference among ethnic groups has never been investigated in detail. Prospective trials with concurrent platinum-containing chemoradiation in unresectable disease were investigated, and a total of 116 treatment arms with 7520 patients were identified. Univariate analysis demonstrated that treatment arms conducted in Asia had significantly lower incidence of severe esophagitis (170/2534, 6.7%, odds ratio 0.289) than in other nations (1025/4986, 20.6%). In the multivariable model, Asian/non-Asian ethnicity, multi-/single-agent, and split are jointly significant predictors after adjusting for all possible factors. This study suggests that severe esophagitis occurs less frequently in the Asian population compared to the non-Asian population.

Entities:  

Keywords:  Chemoradiation; esophagitis; non-small cell lung cancer

Year:  2014        PMID: 26767053      PMCID: PMC4704333          DOI: 10.1111/1759-7714.12141

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  10 in total

1.  Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.

Authors:  Yoshihiko Segawa; Katsuyuki Kiura; Nagio Takigawa; Haruhito Kamei; Shingo Harita; Shunkichi Hiraki; Yoichi Watanabe; Keisuke Sugimoto; Takuo Shibayama; Toshiro Yonei; Hiroshi Ueoka; Mitsuhiro Takemoto; Susumu Kanazawa; Ichiro Takata; Naoyuki Nogami; Katsuyuki Hotta; Akio Hiraki; Masahiro Tabata; Keitaro Matsuo; Mitsune Tanimoto
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

2.  Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis.

Authors:  R S Pritchard; S P Anthony
Journal:  Ann Intern Med       Date:  1996-11-01       Impact factor: 25.391

3.  Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.

Authors:  Nobuyuki Yamamoto; Kazuhiko Nakagawa; Yasumasa Nishimura; Kayoko Tsujino; Miyako Satouchi; Shinzoh Kudo; Toyoaki Hida; Masaaki Kawahara; Koji Takeda; Nobuyuki Katakami; Toshiyuki Sawa; Soichiro Yokota; Takashi Seto; Fumio Imamura; Hideo Saka; Yasuo Iwamoto; Hiroshi Semba; Yasutaka Chiba; Hisao Uejima; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

Review 4.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

Authors:  Anne Aupérin; Cecile Le Péchoux; Estelle Rolland; Walter J Curran; Kiyoyuki Furuse; Pierre Fournel; Jose Belderbos; Gerald Clamon; Hakki Cuneyt Ulutin; Rebecca Paulus; Takeharu Yamanaka; Marie-Cecile Bozonnat; Apollonia Uitterhoeve; Xiaofei Wang; Lesley Stewart; Rodrigo Arriagada; Sarah Burdett; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

5.  Association between single nucleotide polymorphisms of the transforming growth factor β1 gene and the risk of severe radiation esophagitis in patients with lung cancer.

Authors:  Jose Luis Lopez Guerra; Daniel Gomez; Qingyi Wei; Zhengshen Liu; Li-E Wang; Xianglin Yuan; Yan Zhuang; Ritusko Komaki; Zhongxing Liao
Journal:  Radiother Oncol       Date:  2012-09-27       Impact factor: 6.280

6.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

7.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

Authors:  Walter J Curran; Rebecca Paulus; Corey J Langer; Ritsuko Komaki; Jin S Lee; Stephen Hauser; Benjamin Movsas; Todd Wasserman; Seth A Rosenthal; Elizabeth Gore; Mitchell Machtay; William Sause; James D Cox
Journal:  J Natl Cancer Inst       Date:  2011-09-08       Impact factor: 13.506

8.  Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.

Authors:  K Furuse; K Kubota; M Kawahara; N Kodama; M Ogawara; M Akira; S Nakajima; M Takada; Y Kusunoki; S Negoro
Journal:  J Clin Oncol       Date:  1995-04       Impact factor: 44.544

9.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

Review 10.  Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis.

Authors:  David A Palma; Suresh Senan; Cary Oberije; Jose Belderbos; Núria Rodríguez de Dios; Jeffrey D Bradley; R Bryan Barriger; Marta Moreno-Jiménez; Tae Hyun Kim; Sara Ramella; Sarah Everitt; Ramesh Rengan; Lawrence B Marks; Kim De Ruyck; Andrew Warner; George Rodrigues
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-09-10       Impact factor: 7.038

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.